NCT05683717 2023-11-21
A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies
TransThera Sciences (Nanjing), Inc.
Phase 1 Recruiting
Clinical Trials
5 trialsNCT02018861 2023-09-28
A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)
Incyte Corporation
Phase 1/2 Completed
NCT05275504 2022-06-09
Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies
TransThera Sciences (Nanjing), Inc.
Phase 1 Unknown
NCT03642496 2018-08-23
Clinical Study of ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies
First Affiliated Hospital Xi'an Jiaotong University
Phase EARLY_PHASE1 Unknown
NCT01775631 2017-03-31
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
Bristol-Myers Squibb
Phase 1 Completed